InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
At Electromedical Technologies, we believe results speak louder than words. Since ...
At Electromedical Technologies, we believe resu...
GuruMD directs patients away from costly emergency rooms and urgent cares by provi...
GuruMD directs patients away from costly emerge...
NantHealth is a next-generation, evidence-based, personalized healthcare company e...
NantHealth is a next-generation, evidence-based...
Hoth Therapeutics is a development stage biopharmaceutical company focused on prop...
Hoth Therapeutics is a development stage biopha...
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pha...
Established in 2007, and headquartered in Wakef...
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...
Corbus Pharmaceuticals Holdings, Inc. is a Phas...
Join the National Investor Network and get the latest information with your interests in mind.